Company intelligence / Profile preview
IpiNovyx Bio
New York City, New York, USAipinovyx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
IpiNovyx Bio is advancing a proprietary platform of highly selective, reversible immunoproteasome inhibitors with promising preclinical efficacy and safety profiles. The company is preparing to submit its first IND application and enter clinical trials targeting autoimmune and inflammatory diseases. Their compounds are designed to modulate immune responses without killing immune cells, potentially offering a safer alternative to current immunosuppressive therapies.
- Therapeutic areas
- ImmunologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Weill Cornell MedicineHospital for Special Surgery Research InstituteTri-Institutional Therapeutics Discovery InstituteEli LillyViva BioInnovator/Viva BiotechOpaleye ManagementAlexandria Venture Investments
Beyond the preview
Go deeper on IpiNovyx Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IpiNovyx Bio.